Business & Regulation

Why we need to shift from reactive to proactive measures in tackling global health challenges.

Choosing which medical congresses to target when launching your new medicine requires careful research and a sound strategy.

Claus Zieler reflects on his time at Astellas and his role at EFPIA.

How AI-driven process optimization could lower costs and improve success rates in drug development.

Claus Zieler from Astellas and EFPIA addresses the challenges facing innovation in Europe, including regulatory burdens and access to medicines.

Kristina Kempf at PTC Therapeutics discusses the importance of strong female role models.

How will the biopharma industry evolve over the next 10 years? We speak with experts from Sartorius and the USP.

Alfred Marchler and Peter Hirst discuss the biggest disruptors shaping the next decade.

Voting is now open for our 2025 Company of the Year Awards.

Technological advances are opening up new drug development opportunities for rare diseases.